Benevolent News Hub

In the media
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020
Intern at BenevolentAI part II: what to expect from your internship
What makes the best tech internships? Learn about what our 2020 interns have been up to, and how interning at Benevolent helped their career development.
Dec 2, 2020
Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
BenevolentAI at NeurIPS 2020: Machine Learning in Drug Discovery
BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.
Nov 17, 2020